Resource Logo
CDC HIV/AIDS/Viral Hepatitis/STD/TB Prevention News Update

UNITED STATES: FDA Advisory Panel Backs Approval of J&J's Hepatitis C Drug




 

Reuters (10.24.2013) Aids Weekly Plus

Reuters reported last week that a US Food and Drug Administration (FDA) advisory committee approved simeprevir, a hepatitis C drug by Johnson & Johnson (J&J). The advisory committee voted 19–0 to approve the drug, which will be used in combination with current hepatitis C drugs peginterferon-alpha and ribavirin. The liver infection, which is transmitted through blood, claims more than 15,000 lives annually in the United States, most often from cirrhosis and liver cancer. The FDA is not required to follow the panel’s advice, although it usually does. J&J is testing simeprevir on adults who have not taken any previous medication or who failed previous therapy.



 


Copyright © 2013 -CDC Prevention News Update, Publisher. All rights reserved to Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.



Information in this article was accurate in October 29, 2013. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.